Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

KemPharm, Inc. (KMPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.6900+0.0900 (+1.96%)
At close: 04:00PM EDT
4.6700 -0.02 (-0.43%)
After hours: 05:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close4.6000
Open4.6000
Bid4.6700 x 3000
Ask4.7900 x 4000
Day's Range4.4700 - 4.7300
52 Week Range4.0000 - 15.6970
Volume224,825
Avg. Volume526,909
Market Cap161.446M
Beta (5Y Monthly)2.96
PE Ratio (TTM)N/A
EPS (TTM)-0.5070
Earnings DateAug 10, 2022 - Aug 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KMPH

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • KemPharm, Inc.
    Analyst Report: AbbVie IncAbbVie, a research-based biopharmaceutical company, was spun off from Abbott Laboratories in January 2013. The company is based in suburban Chicago. The shares are a component of the S&P 500.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • Zacks

    KemPharm (KMPH) Stock Up on Deal to Acquire Orphazyme for $12.8M

    KemPharm (KMPH) inks deal to acquire Orphazyme A/S, which will add to its portfolio the latter's pipeline candidate, arimoclomol, being developed for treating Niemann-Pick disease type C. Shares rise.

  • GlobeNewswire

    KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline

    Arimoclomol is an NDA-stage, revenue-generating investigational drug candidate being developed for the treatment of Niemann-Pick disease type C (NPC), a rare progressive neurodegenerative disease KemPharm plans to refile the New Drug Application (NDA) for arimoclomol in NPC with the U.S. Food and Drug Administration (FDA) as early as the First Quarter of 2023 Conference call and live audio webcast with slide presentation is scheduled for tomorrow, May 16, 2022, at 8:30 a.m., EDT CELEBRATION, Fla

  • GlobeNewswire

    KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates

    Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, May 12, 2022, at 5:00 p.m. ET Filed Investigational New Drug (IND) application with U.S. Food and Drug Administration (FDA) for KP1077, a serdexmethylphenidate (SDX)-based product candidate for idiopathic hypersomnia (IH) Initiation of a Phase 2 trial (KP1077.D01) expected in the second half of 2022, with a second trial in patients with narcolepsy expected to begin the quarter following start of KP1077.D01 Dosed

Advertisement
Advertisement